UNITED STATES SECURITIES AND EXCHANGE COMMISSION ~~Washington, D.C. 20549 _____________________________~~

~~FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ________________ Date of Report (Date of earliest event reported): June 28~~Washington, ~~2007~~D.C. 20549

Alpharma Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) 1-8593 (Commission File Number) 22-2095212 (IRS Employer Identification)
Form 8-K

~~440~~CURRENT ~~Route~~REPORT PURSUANT ~~22,~~TO ~~Bridgewater,~~SECTION ~~New~~13 ~~Jersey~~OR ~~08807~~ 15(~~Address of principal executive offices~~d) ~~(Zip~~OF ~~Code)~~THE SECURITIES ~~Registrant's~~EXCHANGE ~~telephone~~ACT ~~number,~~OF ~~including area code (866) 322-2525 (Former name or former address, if changed since last report)~~1934

~~Item~~Date ~~5.02 Departure~~ of ~~Directors~~Report or(Date ~~Certain Officers; Election~~ of ~~Directors;~~earliest ~~Appointment~~event ofreported): June ~~Certain~~19, ~~Officers; Compensatory Arrangements of Certain Officers~~2008

~~(c) On~~ALPHARMA ~~June 28, 2007, Donald I~~INC. Buzinkai, age 37, entered into an agreement with the Company to become Vice President, Controller and Principal Accounting Officer of the Company, effective on or about August 6, 2007. Mr. Buzinkai is currently a Director, Financial Planning and Analysis at Ingersoll Rand Company. Mr. Buzinkai has been with Ingersoll Rand for over eight years and has held several positions during that time including most recently Director of Financial Shared Services and Vice President, Finance and Controller and Vice President of Human Resources, for the Security and Safety Americas division.

(Exact Name of registrant as specified in its charter)

~~SIGNATURES~~Delaware (State or Other Jurisdiction of Incorporation) 1-8593 (Commission File Number) 22-2095212 (IRS Employer Identification No.)

~~Pursuant~~440 toRoute ~~the~~22, ~~requirements~~Bridgewater ofNew ~~the~~Jersey ~~Securities~~08807 ~~Exchange~~(Address ~~Act~~ of ~~1934,~~principal ~~the~~executive ~~registrant~~offices) ~~has~~(866) ~~duly~~322-2525 ~~caused~~(Registrant's ~~this~~telephone ~~report~~number, toincluding bearea ~~signed~~code) onNot ~~its~~Applicable ~~behalf~~Former byname ~~the~~or ~~undersigned~~former ~~hereunto~~address, ~~duly~~if ~~authorized.~~changed since last report

~~ALPHARMA~~Check ~~INC.~~the ~~By:~~appropriate ~~/s/~~box ~~Jeffrey~~below S.if ~~Campbell~~the ~~Jeffrey~~Form S.8-K ~~Campbell~~filing ~~Executive~~is ~~Vice~~intended ~~President~~to &simultaneously ~~Chief~~satisfy ~~Financial~~the ~~Officer~~filing obligation of the registrant under any of the following provisions:

~~Date: July~~[ ] 5,Written ~~2007~~communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 19, 2008, Alpharma Inc. (the "Registrant") announced a change in the role of Ronald N. Warner, Ph.D., one of its named executive officers. Dr. Warner, the President of the Registrant's Pharmaceuticals Division since 2005, has now been appointed to the position of Executive Vice President and Chief Scientific Officer, effective immediately. The Registrant issued a press release on June 19, 2008 announcing this change, a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1	Press release issued by the Registrant on June 19, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALPHARMA INC.

(Registrant)

By: /s/ Thomas J. Spellman III

Thomas J. Spellman III

Executive Vice President, General Counsel

& Corporate Secretary

Date: June 24, 2008

Alpharma Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation)	1-8593 (Commission File Number)	22-2095212 (IRS Employer Identification)

Filing Compare · ALPHARMA INC